Physician
Rural Urgent Care LLC
Rural Urgent Care LLC was paid $26.03M by Medicaid between Jan 2018 and Dec 2024, across 48 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 33% of everything it billed.
33Billing provider infoRURAL URGENT CARE LLC
CENTRE, AL 35960
CENTRE, AL 35960
33aNPI1932586476assigned 05/05/2015
33bProvider typeFamily Medicine Physician
28Total paid$26.03M
24GClaims1,339,324
24DCodes billed48
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Alabama
Rank by total paid#1 of 455
Median peer was paid$57K
This provider vs. median457×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 74,139 | $1.74M | |
| 2019 | 120,237 | $2.48M | |
| 2020 | 122,320 | $2.69M | |
| 2021 | 219,322 | $3.78M | |
| 2022 | 245,649 | $5.03M | |
| 2023 | 318,396 | $6.14M | |
| 2024incomplete | 239,261 | $4.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 33% | 179,708 | 142,784 | $8.67M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 26% | 104,236 | 85,486 | $6.83M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 11% | 412,749 | 166,400 | $2.82M |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 9.2% | 146,183 | 116,534 | $2.39M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.5% | 169,485 | 138,200 | $1.44M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.0% | 24,062 | 18,533 | $1.05M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.2% | 50,078 | 38,343 | $836K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 20,485 | 15,579 | $679K |
| 87634 | 2.5% | 22,429 | 18,409 | $653K | |
| 87807 | <1% | 33,298 | 26,879 | $225K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 42,954 | 33,861 | $218K |
| 99051 | <1% | 16,792 | 14,661 | $57K |
36 more codes
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 785 | $42K |
| 81003 | <1% | 12,447 | $20K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 848 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 29,491 | $13K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 367 | $13K |
| 87631 | <1% | 378 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,815 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 986 | $7K |
| 80305 | <1% | 995 | $5K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,517 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 183 | $4K |
| 90473 | <1% | 1,216 | $3K | |
| 99000 | <1% | 6,333 | $3K | |
| 99205 | Prolong outpt/office vis | <1% | 37 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,104 | $3K |
| 87809 | <1% | 433 | $2K | |
| 81025 | <1% | 1,128 | $2K | |
| 86308 | <1% | 378 | $579.96 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 21 | $410.59 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 583 | $403.81 |
| 86318 | <1% | 53 | $164.92 | |
| 74018 | <1% | 19 | $122.29 | |
| 82947 | <1% | 32 | $56.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 108 | $38.40 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 48 | $34.02 |
| 3074F | 0% | 21,994 | $0.00 | |
| 3079F | 0% | 5,491 | $0.00 | |
| 3075F | 0% | 513 | $0.00 | |
| 3080F | 0% | 463 | $0.00 | |
| A9150 | Non-prescription drugs | 0% | 27 | $0.00 |
| 3078F | 0% | 10,721 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 448 | $0.00 |
| 3077F | 0% | 821 | $0.00 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | 0% | 41 | $0.00 |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 24 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialESKILDSEN, SAM (MANAGING PARTNER)